Compare Stocks

Date Range: 

 Cara TherapeuticsOlema PharmaceuticalsTheravance BiopharmaApplied Molecular TransportAclaris Therapeutics
SymbolNASDAQ:CARANASDAQ:OLMANASDAQ:TBPHNASDAQ:AMTINASDAQ:ACRS
Price Information
Current Price$12.41$21.95$19.18$43.78$23.34
52 Week RangeBuyBuyBuyBuyBuy
MarketRank™
Overall Score1.81.61.62.00.8
Analysis Score3.53.53.53.50.0
Community Score3.14.32.43.62.6
Dividend Score0.00.00.00.00.0
Ownership Score1.70.01.72.50.8
Earnings & Valuation Score0.60.00.60.60.6
Analyst Ratings
Consensus RecommendationBuyBuyBuyBuyBuy
Consensus Price Target$32.00$60.67$33.14$68.75N/A
% Upside from Price Target157.86% upside176.39% upside72.80% upside57.04% upsideN/A
Trade Information
Market Cap$628.53 million$867.67 million$1.29 billion$1.62 billion$1.20 billion
Beta1.7N/A0.94N/A1.2
Average Volume1,045,991150,375332,764231,0972,286,868
Sales & Book Value
Annual Revenue$19.89 millionN/A$73.41 millionN/A$4.23 million
Price / Sales31.22N/A17.04N/A287.39
CashflowN/AN/AN/AN/AN/A
Price / CashN/AN/AN/AN/AN/A
Book Value$4.66 per shareN/A($3.94) per shareN/A$1.69 per share
Price / Book2.66N/A-4.87N/A13.81
Profitability
Net Income$-106,370,000.00N/A$-236,460,000.00$-28,040,000.00$-161,350,000.00
EPS($2.49)N/A($4.25)N/A($2.25)
Trailing P/E RatioN/A0.00N/A0.00N/A
Forward P/E RatioN/AN/AN/AN/AN/A
P/E GrowthN/AN/AN/AN/AN/A
Net Margins-360.35%N/A-345.16%N/A-941.07%
Return on Equity (ROE)-64.36%N/AN/AN/A-104.00%
Return on Assets (ROA)-53.22%N/A-51.60%N/A-64.47%
Dividend
Annual PayoutN/AN/AN/AN/AN/A
Dividend YieldN/AN/AN/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity RatioN/AN/AN/AN/A0.26%
Current Ratio8.00%N/A4.32%19.39%4.54%
Quick Ratio8.00%N/A4.32%19.39%4.54%
Ownership Information
Institutional Ownership Percentage67.01%N/A80.41%51.99%59.10%
Insider Ownership Percentage5.70%N/A5.90%N/A8.20%
Miscellaneous
Employees80363598057
Shares Outstanding50.04 million40.17 million65.22 million35.25 million52.09 million
Next Earnings Date5/10/2021 (Confirmed)6/16/2021 (Estimated)8/5/2021 (Estimated)6/18/2021 (Estimated)8/6/2021 (Estimated)
OptionableOptionableNot OptionableOptionableNot OptionableOptionable
SourceHeadline
Aclaris Therapeutics (NASDAQ:ACRS) Issues  Earnings ResultsAclaris Therapeutics (NASDAQ:ACRS) Issues Earnings Results
americanbankingnews.com - May 8 at 12:08 PM
Aclaris Therapeutics (ACRS) Reports Q1 Loss, Tops Revenue EstimatesAclaris Therapeutics (ACRS) Reports Q1 Loss, Tops Revenue Estimates
finance.yahoo.com - May 7 at 12:44 PM
Aclaris: Q1 Earnings SnapshotAclaris: Q1 Earnings Snapshot
seattlepi.com - May 7 at 7:44 AM
Aclaris Therapeutics Reports First Quarter 2021 Financial Results and Provides a Corporate UpdateAclaris Therapeutics Reports First Quarter 2021 Financial Results and Provides a Corporate Update
finance.yahoo.com - May 7 at 7:44 AM
Aclaris Therapeutics, Inc. Forecasted to Earn FY2022 Earnings of ($1.37) Per Share (NASDAQ:ACRS)Aclaris Therapeutics, Inc. Forecasted to Earn FY2022 Earnings of ($1.37) Per Share (NASDAQ:ACRS)
americanbankingnews.com - May 6 at 11:42 AM
Kamil Ali-Jackson Sells 15,000 Shares of Aclaris Therapeutics, Inc. (NASDAQ:ACRS) StockKamil Ali-Jackson Sells 15,000 Shares of Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Stock
americanbankingnews.com - May 5 at 11:08 PM
Insider Selling: Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Insider Sells 15,000 Shares of StockInsider Selling: Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Insider Sells 15,000 Shares of Stock
americanbankingnews.com - May 5 at 11:08 PM
Aclaris Therapeutics, Inc. (NASDAQ:ACRS)Metrics You Need to Know Right NowAclaris Therapeutics, Inc. (NASDAQ:ACRS)Metrics You Need to Know Right Now
stocksregister.com - May 1 at 2:48 PM
Aclaris Therapeutics (NASDAQ:ACRS) Rating Lowered to Sell at Zacks Investment ResearchAclaris Therapeutics (NASDAQ:ACRS) Rating Lowered to Sell at Zacks Investment Research
marketbeat.com - April 27 at 4:51 PM
HC Wainwright Initiates Coverage on Aclaris Therapeutics (NASDAQ:ACRS)HC Wainwright Initiates Coverage on Aclaris Therapeutics (NASDAQ:ACRS)
americanbankingnews.com - April 27 at 9:12 AM
Aclaris Therapeutics Inc (ACRS) President and CEO Neal Walker Sold $805,200 of SharesAclaris Therapeutics Inc (ACRS) President and CEO Neal Walker Sold $805,200 of Shares
uk.finance.yahoo.com - April 27 at 6:57 AM
Aclaris Therapeutics, Inc. (NASDAQ:ACRS) CFO Frank Ruffo Sells 30,000 SharesAclaris Therapeutics, Inc. (NASDAQ:ACRS) CFO Frank Ruffo Sells 30,000 Shares
americanbankingnews.com - April 26 at 10:50 PM
Aclaris Therapeutics (NASDAQ:ACRS) Trading Down 4.1%Aclaris Therapeutics (NASDAQ:ACRS) Trading Down 4.1%
americanbankingnews.com - April 26 at 1:46 PM
Is ACRS Stock A Buy or Sell?Is ACRS Stock A Buy or Sell?
finance.yahoo.com - April 26 at 7:23 AM
Aclaris Therapeutics (NASDAQ:ACRS) Shares Gap Up to $26.46Aclaris Therapeutics (NASDAQ:ACRS) Shares Gap Up to $26.46
americanbankingnews.com - April 21 at 10:38 AM
Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Short Interest Up 41.5% in MarchAclaris Therapeutics, Inc. (NASDAQ:ACRS) Short Interest Up 41.5% in March
americanbankingnews.com - April 18 at 1:14 AM
Aclaris Therapeutics, Inc. (NASDAQ:ACRS) share price rebounds 96.18% from the lows – but can it keep going?Aclaris Therapeutics, Inc. (NASDAQ:ACRS) share price rebounds 96.18% from the lows – but can it keep going?
marketingsentinel.com - April 17 at 6:00 PM
Aclaris Therapeutics Stock Appears To Be Significantly OvervaluedAclaris Therapeutics Stock Appears To Be Significantly Overvalued
finance.yahoo.com - April 1 at 8:23 AM
Aclaris Therapeutics Completes Enrollment in its Phase 2a Clinical Trial of ATI-1777 for ...Aclaris Therapeutics Completes Enrollment in its Phase 2a Clinical Trial of ATI-1777 for ...
apnews.com - March 16 at 9:44 AM
Aclaris Therapeutics Completes Enrollment in its Phase 2a Clinical Trial of ATI-1777 for Moderate to Severe Atopic DermatitisAclaris Therapeutics Completes Enrollment in its Phase 2a Clinical Trial of ATI-1777 for Moderate to Severe Atopic Dermatitis
finance.yahoo.com - March 15 at 8:29 AM
Aclaris Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides a ...Aclaris Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides a ...
apnews.com - February 26 at 9:58 AM
Aclaris: 4Q Earnings Snapshot | Raleigh News & ObserverAclaris: 4Q Earnings Snapshot | Raleigh News & Observer
newsobserver.com - February 25 at 1:29 PM
Aclaris Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides a Corporate UpdateAclaris Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides a Corporate Update
finance.yahoo.com - February 25 at 8:29 AM
Aclaris Therapeutics to Participate in Upcoming Investor ConferencesAclaris Therapeutics to Participate in Upcoming Investor Conferences
finance.yahoo.com - February 22 at 9:00 AM
Aclaris Therapeutics to Participate in the 10th Annual SVB Leerink Global Healthcare ConferenceAclaris Therapeutics to Participate in the 10th Annual SVB Leerink Global Healthcare Conference
finance.yahoo.com - February 10 at 9:06 AM
Gaining Ground After A Tough Couple Of WeeksGaining Ground After A Tough Couple Of Weeks
finance.yahoo.com - January 25 at 7:34 PM
DateCompanyBrokerageAction
5/5/2021Cara TherapeuticsNeedham & Company LLCLower Price Target
9/8/2020Cara TherapeuticsCanaccord GenuityReiterated Rating
5/19/2020Cara TherapeuticsCantor FitzgeraldBoost Price Target
4/21/2020Cara TherapeuticsHC WainwrightBoost Price Target
7/30/2019Cara TherapeuticsPiper Jaffray CompaniesBoost Price Target
5/29/2019Cara TherapeuticsLaidlawBoost Price Target
2/6/2019Cara TherapeuticsJefferies Financial GroupInitiated Coverage
1/15/2019Cara TherapeuticsBank of AmericaInitiated Coverage
12/14/2020Olema PharmaceuticalsJPMorgan Chase & Co.Initiated Coverage
12/14/2020Olema PharmaceuticalsCowenInitiated Coverage
5/5/2021Theravance BiopharmaSVB LeerinkLower Price Target
3/8/2021Theravance BiopharmaMorgan StanleyLower Price Target
11/23/2020Theravance BiopharmaEvercore ISIReiterated Rating
8/7/2020Theravance BiopharmaPiper SandlerLower Price Target
11/6/2019Theravance BiopharmaRobert W. BairdUpgrade
3/23/2021Applied Molecular TransportJMP SecuritiesInitiated Coverage
10/11/2019Aclaris TherapeuticsWilliam BlairReiterated Rating
(Data available from 5/10/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.